Top news of April: Tree nut oral immunotherapy, asthma care in prison, more
Click Here to Manage Email Alerts
Healio compiled the most-read news in allergy, asthma and immunology posted in April.
Highlights included studies of oral and sublingual immunotherapy, the state of asthma care in the correctional system, percentages of patients who outgrow their food allergies, phenotypes and treatment in eosinophilic esophagitis, and more.
Tree nut oral immunotherapy deemed safe, tolerable for preschoolers
OIT for tree nut allergies was safe and tolerable among a preschool population with results comparable to OIT for peanut allergy, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice. Also, Matthew Greenhawt, MD, MBA, MSc, FACAAI, of Children’s Hospital Colorado, shares his Perspective. Read more.
Asthma, other chronic conditions undertreated among incarcerated individuals
Incarcerated individuals account for 0.85% of the total population in the United States but only 0.15% of asthma prescriptions, Jill Curran, MS, of Johns Hopkins Bloomberg School of Public Health, told Healio, with a 5.45-fold magnitude of difference between disease burden and treatment. Read more.
About one-quarter of patients outgrow food allergies
Based on a survey, 25.1% of children and 25.5% of adults developed an oral tolerance to one or more food allergens, Christopher M. Warren, PhD, of the Center for Food Allergy & Asthma Research, told Healio at the 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting in San Antonio. Read more.
Q&A: Sublingual immunotherapy safe, effective for children with peanut allergy
Edwin H. Kim, MD, MS, of UNC Pediatric Allergy & Immunology, explains how sublingual immunotherapy is a promising alternative to OIT, which comes with a risk for allergic reactions and a significant treatment burden, for children aged 2 to 12 years with peanut allergy. Read more.
Eosinophilic esophagitis associated with increased number, severity of food allergies
Differences in number and severity of food allergies between patients with food allergy who do or do not have eosinophilic esophagitis as well may indicate a more severe food allergy phenotype, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice. Also, Jennifer Bufford, MS, CRQM, CCRP, CCRC, of Food Allergy Research & Education, shares her Perspective. Read more.
Comorbid conditions associated with time to, severity of alpha-gal reactions
Symptom patterns in alpha-gal syndrome suggest concurrent diseases such as autoimmune disease and vitamin D deficiency, Jennifer Platt, DrPH, of the University of North Carolina Gillings School of Global Public Health, told Healio at the 2023 AAAAI Annual Meeting. Read more.
Q&A: Peptide resets immune system to treat eosinophilic esophagitis
Roly Foulkes, PhD, chief scientific officer at Revolo, explains how the company’s ‘1104 first-in-class peptide leads to reductions in esophageal intraepithelial eosinophil count, increases in regulatory B and T cells that suppress inflammatory immune responses and positive changes in the expression of key genes related to eosinophilic esophagitis. Read more.
FDA approves Hyqvia for children with primary immunodeficiency
The FDA has approved a supplemental biologics license application for the use of Hyqvia (Ig infusion 10% [Human] with recombinant human hyaluronidase), which is a subcutaneous immune globulin infusion that can be administered every 3 or 4 weeks, among children aged 2 to 16 years. Read more.
Older patients with chronic urticaria present with unique characteristics
Older patients with chronic urticaria have characteristics that are unique compared with younger patients such as high rates of autoimmunity and malignancy, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice. Also, Nicholas Gulati, MD, PhD, of the Icahn School of Medicine at Mount Sinai, shares his Perspective. Read more.
Baseline FeNO levels predict response to dupilumab among patients with asthma
Fractional exhaled nitric oxide is a useful biomarker in predicting how patients with uncontrolled moderate to severe asthma will respond to dupilumab, independent of eosinophil levels and other clinical characteristics, reported a study in The Journal of Allergy and Clinical Immunology: In Practice. Also, Healio Allergy/Asthma Peer Perspective Board Member Mark Corbett, MD, shares his Perspective. Read more.